Press Releases by "Eisai Co., Ltd."

• Lyrica® has been approved for treatment of postherpetic neuralgia
  [ Pharmaceuticals | 2010-04-16]
• Eisai Submits Regulatory Applications for Investigational Anticancer Agent Eribulin Mesylate (E7389) in Japan, the United States and Europe
  [ Pharmaceuticals | 2010-03-31]
• Notice Concerning Shelf Registration for Issuance of Stock Options
  [ Pharmaceuticals | 2010-03-29]
• Eisai to Continue Eritoran (E5564) Phase III Severe Sepsis Trial
  [ Pharmaceuticals | 2010-03-26]
• FDA Approves Five-Day Dosing Regimen for Dacogen®
  [ Pharmaceuticals | 2010-03-12]
• Eisai Breaks Ground for New Morphotek Pilot Plant
  [ Pharmaceuticals | 2010-03-09]
• Eisai Introduces Travelmin® Churop Lemon Flavor
  [ Pharmaceuticals | 2010-03-02]
• Eisai Launches REVOVIR® in the Philippines for the Treatment of Chronic Hepatitis B
  [ Pharmaceuticals | 2010-02-24]
• Fully Human Monoclonal Anti-TNF- Antibody HUMIRA® Receives Approval as Japan's First Biological Agent for Psoriasis
  [ Pharmaceuticals | 2010-01-20]
• Eisai Group Contributes to Haiti Earthquake Relief Efforts
  [ Pharmaceuticals | 2010-01-19]
• Eisai Submits Application for Additional Indication of Anti-arrhythmic Agent Tambocor® Tablets for Tachyarrhythmia in Paediatric Patients in Japan
  [ Pharmaceuticals | 2010-01-14]
• Eisai Introduces New Chocola BB Series Pharmaceutical Product “Chocola BB® Royal T”
  [ Pharmaceuticals | 2010-01-12]
• Eisai Completes Acquisition of AkaRx, Inc. in the United States
  [ Pharmaceuticals | 2010-01-07]
• Submission of the New Drug Application for Pancreatic Enzyme Replacement Therapy Agent SA-001 in Japan
  [ Pharmaceuticals | 2009-12-24]
• Eisai Initiates Procedures to Acquire AkaRx, Inc. in the United States
  [ Pharmaceuticals | 2009-12-18]
• Eisai Opens New Manufacturing and Process Research Base in India
  [ Pharmaceuticals | 2009-12-17]
• Eisai Launches New Oral Jelly Formulation of Aricept®
  [ Pharmaceuticals | 2009-12-01]
• FDA Accepts for Review Eisai's NDA for Aricept® 23mg Extended Release Tablets in the United States
  [ Pharmaceuticals | 2009-11-25]
• Eisai Launches Sedative-Hypnotic Agent LUSEDRA™ Injection CIV in the United States
  [ Pharmaceuticals | 2009-11-17]
• Eisai Launches Sedative-Hypnotic Agent LUSEDRA™ Injection CIV in the United States
  [ Pharmaceuticals | 2009-11-17]

Most Popular: "Eisai Co., Ltd."